KLOW isn’t a single peptide. It’s a nickname for a four-peptide blend packed into one 80 mg vial, and the name is essentially an acronym for what’s inside: the K is KPV, and the rest is a nod to the trio it’s built on — GHK-Cu, BPC-157 and TB-500. Most people first meet “KLOW” as a word on a vendor’s product page, with zero explanation of the four molecules they’re actually looking at.
This article fixes that. By the end you’ll know exactly what each of the four peptides is, why they were combined into one vial, where the name came from, and — critically — what the research does and does not support. One frame to set before we go further: everything here is described for research and educational purposes only. Nothing below is medical advice, a recommendation to use any peptide, or a claim that KLOW treats, cures or prevents anything. The blend has never been tested as a blend in a human clinical trial, and two of its components are not approved for human use.
Research-use-only. The peptides discussed here are sold and studied for laboratory and research purposes. This page explains what KLOW is; it is not medical advice and not a recommendation to use any compound in humans. For dosing questions, see the protocol page linked below — this article deliberately contains no doses.
What is KLOW?
KLOW is a combination product: four separate peptides lyophilized (freeze-dried) together into a single vial, so they can be reconstituted and studied as one preparation instead of four. It is not a novel molecule, not a patented drug, and not a single active ingredient. When someone says “I’m researching KLOW,” they mean they’re working with a blend of GHK-Cu, BPC-157, TB-500 and KPV in fixed proportions.
The distinction matters because almost every downstream question — what it does, how it’s handled, what the evidence says — depends on understanding that KLOW is four things wearing one label. If you’ve only ever seen the four-letter word, this is the single most important sentence to absorb: KLOW = a blend, not a molecule. You can find short definitions of each component in GHK-Cu, BPC-157, TB-500 and KPV in our peptide glossary.
The KLOW formula at a glance
The reference formulation this site works from is an 80 mg vial split across the four peptides, and the split is heavily weighted toward one component. Here is the exact composition:
| Peptide | Amount | Share of vial | One-line role |
|---|---|---|---|
| GHK-Cu | 50 mg | 62.5% | Copper tripeptide — skin/collagen/remodeling focus |
| BPC-157 | 10 mg | 12.5% | Gastric-derived peptide — tissue/gut repair in animal models |
| TB-500 | 10 mg | 12.5% | Thymosin β4 fragment — cell migration and repair signaling |
| KPV | 10 mg | 12.5% | α-MSH tail tripeptide — anti-inflammatory signaling |
| Total | 80 mg | 100% |
Why GHK-Cu is the biggest slice (62.5% of the vial)
GHK-Cu occupies more than three-fifths of the vial — five times the amount of any other component. A formulation might weight it this heavily for a couple of practical reasons. GHK-Cu is the most extensively studied of the four peptides, with the deepest body of published work behind it, much of it on skin and connective tissue; it’s also generally researched at higher amounts than the others. Whatever the formulator’s exact reasoning, the takeaway is simple: KLOW is, by mass, mostly a GHK-Cu preparation with three smaller repair-and-anti-inflammatory peptides added. That has downstream implications — most notably a meaningful copper load, since GHK-Cu carries a copper ion on every molecule.
Meet the four peptides
Each of KLOW’s components is a distinct molecule with its own discovery story and its own separate research literature. Here’s the short version of each.
GHK-Cu — the copper tripeptide
GHK-Cu is glycyl-L-histidyl-L-lysine bound to a copper ion — a tiny three-amino-acid peptide first isolated from human plasma in 1973 by Loren Pickart. In preclinical and topical research it has been associated with collagen and connective-tissue remodeling, fibroblast activity, and wound-related processes. Reviews of the gene-level and skin-regeneration data describe a molecule that appears to influence a broad set of repair and remodeling pathways in cell and animal systems (Pickart & Margolina, 2018; GHK skin-regeneration review, 2015). Of the four, GHK-Cu has the most human and topical data — though “most” is relative, and the strongest evidence is on skin rather than systemic injectable use.
BPC-157 — the “body protection compound”
BPC-157 is a 15-amino-acid peptide (a pentadecapeptide) corresponding to a partial sequence identified in gastric juice. In animal models it has been studied for tendon, ligament, muscle and gut-mucosal repair, and for effects on angiogenesis (new blood-vessel formation). A 2025 literature and patent review catalogs this largely preclinical mechanism work while stating plainly that there are no comprehensive human clinical studies establishing its effects (Jozwiak et al., 2025). In short: a strong, interesting animal signal, but thin human data.
TB-500 — the synthetic thymosin β4 fragment
TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring protein first isolated in the 1960s. Tβ4’s biology centers on actin regulation — it binds and sequesters actin monomers, a mechanism tied to cell migration and, by extension, to wound repair and re-epithelialization in research models. Two things are worth separating here: the full-length thymosin β4 molecule has reached clinical development (for example, the RGN-259 program), whereas TB-500 the fragment itself remains an investigational research compound, not an approved drug.
KPV — the α-MSH tail tripeptide
KPV is lysine-proline-valine (Lys-Pro-Val), the C-terminal three-amino-acid tail of the hormone alpha-melanocyte-stimulating hormone (α-MSH). Its research interest is anti-inflammatory: in preclinical models it has been associated with inhibition of NF-κB signaling and downregulation of inflammatory mediators, with much of the work coming from colitis, dermatitis and related inflammatory-disease models (building on the broader α-MSH fragment literature). Notably, most KPV delivery evidence comes from oral or local routes rather than systemic injection.
Why blend them? The rationale behind combining four peptides
The theory: complementary mechanisms
The stated logic behind KLOW is that its four peptides cover complementary axes of a repair response. In this framing, BPC-157 and TB-500 form a tissue-repair backbone; GHK-Cu adds a skin, collagen and remodeling dimension; and KPV contributes an anti-inflammatory, NF-κB-dampening angle. On paper, combining “repair + remodeling + anti-inflammatory” into one preparation has an appealing tidiness.
It’s essential to label this for what it is: a theory, not a proven result. The idea that these mechanisms complement each other is inferred from what each peptide appears to do individually, in separate studies. That’s a hypothesis about how they might work together — not evidence that they do.
The catch: no blend has been tested as a blend
Here is the honest limitation at the heart of every KLOW discussion: the blend has never been studied as a blend. The four peptides have been researched individually, in different labs, in different models, at different amounts, mostly not together. No published study has administered this specific four-peptide combination and measured what happens. So any claim of “synergy” is an assumption layered on top of single-component data, not a demonstrated finding. Combining molecules can just as easily produce interactions, redundancy or added variables as it can produce synergy — we simply don’t have the combined data to know. For a fuller side-by-side of how KLOW stacks up against related formulations, see our KLOW vs GLOW vs Wolverine comparison.
Where does KLOW come from?
KLOW has no single inventor and no official product owner. It’s a market formulation — a combination that vendors assembled and a community named — rather than a branded, patented drug from one manufacturer. The name itself is a community coinage: an acronym referencing KPV alongside the GHK-Cu / BPC-157 / TB-500 trio. That informal origin has a practical consequence: vendor ratios vary. Some sellers offer an even 20/20/20/20 split (equal parts of each peptide), while the reference formulation this site works from is the 50/10/10/10 arrangement in an 80 mg vial described above. Because “KLOW” isn’t a regulated, standardized product, always check the specific composition of the vial you’re reading about — two products with the same four-letter name can differ significantly in what’s actually inside.
What’s the research status of KLOW?
Two layers matter here. At the component level, each peptide has its own evidence base: GHK-Cu has the most, including human and topical/skin data; BPC-157 and TB-500 are supported mostly by cell and animal work with minimal human data; KPV has preclinical anti-inflammatory data concentrated in gut and skin models. You can explore the individual compounds via our single-peptide dosage index.
At the blend level, the status is straightforward: a search of registered clinical trials turns up no human clinical trial of the KLOW blend. Zero. Everything said about KLOW-as-a-product is extrapolation from single-component studies.
On regulation: BPC-157 and TB-500 are not FDA-approved for human use. BPC-157’s status has been in flux — it was removed from the FDA’s compounding Category 2 list in April 2026, but that removal does not mean it’s authorized for compounding. It currently sits in a regulatory gray zone, with a Pharmacy Compounding Advisory Committee (PCAC) review scheduled. None of this should be read as approval or endorsement; it’s context for why these compounds are handled as research materials rather than medicines.
How is KLOW handled in research settings?
In a research context, KLOW arrives as a lyophilized (freeze-dried) powder and is reconstituted with bacteriostatic water before use — the same general workflow as any single peptide, just with four molecules already combined in the vial. Because this article is definitional, it deliberately stops at the concept. We do not provide dosing numbers here.
For anything quantitative — how much bacteriostatic water to add, what concentration results, and how it’s dosed in research — use these resources instead: the KLOW 80 mg dosage and reconstitution protocol is the primary reference for all numbers; the step-by-step peptide reconstitution guide walks through the mixing procedure; and the reconstitution & dosage calculator lets you run concentrations yourself.
KLOW quick FAQ
What does KLOW stand for? It’s an acronym-style nickname referencing its four peptides — KPV plus the GHK-Cu, BPC-157 and TB-500 trio. It’s a community/market coinage, not an official brand name.
Is KLOW one peptide or four? Four. KLOW is a blend of four separate peptides in a single vial, not one molecule.
Is KLOW FDA-approved? No. The blend has no approval, and two of its components — BPC-157 and TB-500 — are not FDA-approved for human use.
What’s the difference between KLOW and GLOW? GLOW is essentially KLOW minus KPV — the same GHK-Cu, BPC-157 and TB-500 backbone without the anti-inflammatory tripeptide. See the KLOW vs GLOW vs Wolverine comparison for the full side-by-side.
Key takeaways + where to go next
- KLOW is a blend, not a molecule — four peptides (GHK-Cu, BPC-157, TB-500, KPV) in one 80 mg vial.
- The reference split is GHK-Cu 50 mg (62.5%), BPC-157 10 mg, TB-500 10 mg, KPV 10 mg, though vendor ratios vary (a 20/20/20/20 split also exists).
- Each component has its own research base; GHK-Cu is the best-studied, while BPC-157 and TB-500 data are largely preclinical.
- The blend itself has no human clinical trial, and any “synergy” is theoretical.
- The name is a community coinage; there’s no single inventor or official product.
To go deeper: for dosing and mixing, see the KLOW 80 mg dosage and reconstitution protocol; to see how KLOW compares to similar formulations, read the KLOW vs GLOW vs Wolverine comparison; and to explore related preparations, browse all peptide blends.
References
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 2018. PMC6073405.
- GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration (GHK skin-regeneration review), 2015. PMC4508379.
- Jozwiak M, et al. BPC-157 literature and patent review. Pharmaceuticals, 2025. PMC11859134 (mechanism data and explicit note that no comprehensive human clinical studies exist).
- Thymosin beta-4 / TB-500 primary literature on actin regulation, cell migration and wound repair; full-length Tβ4 clinical development (RGN-259 program).
- KPV as the α-MSH C-terminal fragment and NF-κB inhibition; preclinical IBD/colitis and dermatitis models (α-MSH fragment literature).
- FDA compounding status for BPC-157 (Category 2 removal, April 2026; PCAC review scheduled) — regulatory tracking sources.
- ClinicalTrials.gov — searched to confirm the absence of any registered KLOW-blend clinical trial.
Disclaimer — research use only. This article is for educational and informational purposes and describes laboratory research on the individual peptides in the KLOW blend. It is not medical advice, not a diagnosis or treatment recommendation, and not an endorsement or recommendation to use any peptide in humans. The peptides discussed are research compounds not approved by the FDA for human use, and the KLOW blend has not been evaluated in any human clinical trial. Nothing here should be interpreted as a claim that KLOW or any component treats, cures or prevents any condition. Always consult a qualified, licensed healthcare professional before making any health-related decision.
